---
title: "Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention: Clinical trials questions"
description: "Clinical trials questions on Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results and Long-term results. Questions: How were the Shingrix ZOE-50 and ZOE-70 trials designed? How effective is Shingrix vs placebo in adults 50 and older (ZOE-50)? How effective is Shingrix by age group in adults 50 and older? How effective is Shingrix vs placebo in adults 70 and older? 11 further questions follow. 15 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention: Clinical trials questions

Manufacturer: GlaxoSmithKline Biologicals; GlaxoSmithKline  
Prescribing information: [Shingrix](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF)

Questions that apply to every indication of Shingrix are on [Shingrix (Zoster Vaccine Recombinant, Adjuvanted), all indications](https://www.evicenter.com/medical-information/shingrix).

## Clinical trials

<a id="shingrix-trial-design"></a>

### How were the Shingrix ZOE-50 and ZOE-70 trials designed?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “ZOE-50 (Study 1) Design:
>
> Data from ZOE-50 (NCT01165177), a placebo-controlled, observer-blind phase 3 trial conducted in 18 countries in which subjects ≥50 years old were randomized to receive 2 doses (0 and 2 months) of either SHINGRIX (N=7698) or placebo (N=7713). A total of 7344 and 7415 subjects who received SHINGRIX and placebo, respectively, were included in the mTVC analysis. Subjects were followed for the development of HZ and PHN for a median of 3.1 years (range: 0 to 3.7 years).<sup>1,3</sup>
>
>
>
>
> ZOE-70 (Study 2) Design:
>
> Data from ZOE-70 (NCT01165229), a placebo-controlled, observer-blind phase 3 trial conducted in 18 countries in which subjects ≥70 years old were randomized to receive 2 doses (0 and 2 months) of either SHINGRIX (N=6950) or placebo (N=6950). A total of 6541 and 6622 subjects who received SHINGRIX and placebo, respectively, were included in the mTVC analysis. Subjects were followed for the development of HZ and PHN for a median of 3.9 years (range: 0 to 4.5 years).<sup>1,2</sup>
>
>
>
> The primary efficacy analysis (mTVC) in ZOE-50 and ZOE-70 included all subjects who did not develop a confirmed case of HZ within 1 month after the second dose.<sup>1</sup>
>
>
>
>
> Pooled Analysis of ZOE-50 (Study 1) and ZOE-70 (Study 2):
>
> Data from ZOE-50 and ZOE-70 were combined in a prespecified pooled analysis. A total of 8250 and 8346 subjects ≥70 years of age who received SHINGRIX and placebo, respectively, were included in the mTVC. Subjects were followed for the development of HZ and PHN for a median of 4.0 years (range: 0 to 4.5 years).<sup>1,4</sup>
>
>
>
>
> The studies excluded subjects who were immunocompromised, had a history of HZ, were previously vaccinated against varicella or HZ, and patients whose survival was not expected to be at least 4 years, or with conditions that might interfere with study evaluations.<sup>1</sup>”

Source: [SHINGRIX: Vaccine Efficacy, captured 2026-11-13](https://shingrixhcp.com/efficacy-safety/efficacy-data/#:~:text=ZOE%2D50%20%28Study%201%29%20Design%3A,that%20might%20interfere%20with%20study)

<a id="shingrix-renal-transplant"></a>

### Has Shingrix been studied in kidney transplant recipients?

Applies to: Adult renal transplant recipients receiving maintenance immunosuppressive therapy (ZOSTER-041)

> “A measure of the immune response that confers protection against herpes zoster is unknown.”

Source: [SHINGRIX: Post-Renal Transplant, captured 2026-11-14](https://shingrixhcp.com/home-ic/immunogenicity-data/post-renal-transplant/#:~:text=A%20measure%20of%20the%20immune,against%20herpes%20zoster%20is%20unknown.)

> “Study	RENAL TRANSPLANT [ZOSTER-041]
>
> Phase and trial type/Total vaccinated cohort
> 	Phase 3
> Randomized, observer-blind, placebo-controlled study.
> N=264 (TVC<sup>*</sup>)<sup>2</sup>
>
> Patient Population	ABO-compatible allogeneic renal transplant recipients, ≥18 YOA, SHINGRIX (n=132), Placebo (n=132)<sup>2</sup>
>
> Mean age 52.4 [SD±12.6]
>
> Receiving maintenance immunosuppressive therapy for allograft rejection
>
> Stable renal function
>
> Dosing Schedule 	2-dose series (0.5 mL each) administered 1 to 2 months apart, with the first dose given 4 to 18 months post-transplant<sup>2</sup>
> Study Objectives	Evaluation of immunogenicity and safety<sup>2</sup>
>
> Patients were excluded if they were vaccinated against herpes zoster or varicella zoster virus within the 12 months preceding the first dose of study vaccine/placebo or had a clinical history of varicella or herpes zoster within the 12 months preceding the first dose of study vaccine/placebo.<sup>2</sup>”

Source: [SHINGRIX: Post-Renal Transplant, captured 2026-11-14](https://shingrixhcp.com/home-ic/immunogenicity-data/post-renal-transplant/#:~:text=Study%20Design-,Study,within%20the%2012%20months%20preceding%20the%20first%20dose%20of%20study)

> “In the renal transplant study, biopsy-confirmed allograft rejection was reported by 4 of 132 (3%) of subjects 
> who received SHINGRIX and by 7 of 132 (5%) of subjects who received placebo from the first vaccination to 
> study end (approximately 13 months later). Creatinine as a measure of graft function and changes in 
> alloimmunity postvaccination were not systematically evaluated.”

Source: [SHINGRIX: Prescribing information, page 12, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=12)

Note: The study evaluated immunogenicity and safety; the Prescribing Information reports no efficacy result for renal transplant recipients.

<a id="shingrix-hiv"></a>

### Has Shingrix been studied in adults with HIV?

Applies to: Adults aged 18 years and older with HIV (ZOSTER-015)

> “Study	HIV [ZOSTER-015]
> Phase and trial type/Total vaccinated cohort
>
>
> Phase 1/2a 
>
> Randomized, observer-blind, placebo-controlled study. 
>
> N=123 (TVC*)<sup>2</sup>
>
>
> Patient Population	
>
> Patients with HIV ≥18 YOA, mean age 46.0 [SD±10.93] 
>
> SHINGRIX (n=74), Placebo (n=49), with the following ART status<sup>2</sup>:
>
> SHINGRIX:
>
> ART-treated ≥200 CD4+ T cells/mm<sup>3</sup> (n=56)
> ART-treated 50–199 CD4+ T cells/mm<sup>3</sup> (n=9)
> ART-naive ≥500 CD4+ T cells/mm<sup>3</sup> (n=9) 
>
> Placebo:
>
> ART-treated ≥200 CD4+ T cells/mm<sup>3</sup> (n=38)
> ART-treated 50–199 CD4+ T cells/mm<sup>3</sup> (n=5)
> ART-naive ≥500 CD4+ T cells/mm<sup>3</sup> (n=6) 
>
> Dosing Schedule 	
>
> Patients were administered 0.5mL of either SHINGRIX or placebo on a 0-, 2-, and 6-month schedule; however, administration of the third dose of SHINGRIX is outside of the approved dosing schedule for SHINGRIX.<sup>2,3</sup> Data regarding immunogenicity post-dose 3 are not presented.
>
>
> Study Objectives	Evaluation of immunogenicity and safety<sup>2</sup>
> Patients were excluded if they were vaccinated against herpes zoster or varicella zoster virus within the 12 months preceding the first dose of study vaccine/placebo or had a clinical history of varicella or herpes zoster within the 12 months preceding the first dose of study vaccine/placebo.<sup>2</sup>”

Source: [SHINGRIX: Human Immunodeficiency Virus, captured 2026-11-14](https://shingrixhcp.com/home-ic/immunogenicity-data/human-immunodeficiency-virus/#:~:text=Study%20Design-,Study,within%20the%2012%20months%20preceding%20the%20first%20dose%20of%20study)

> “In the HIV study, at least 1 event of worsening HIV condition was reported by 9 of 74 (12%) of subjects who 
> received SHINGRIX and by 5 of 49 (10%) of subjects who received placebo from the first vaccination to study 
> end.”

Source: [SHINGRIX: Prescribing information, page 12, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=12)

Note: The study used a 3-dose schedule; the page states that a third dose is outside the approved dosing schedule.

## Study results

<a id="shingrix-efficacy-50-and-older"></a>

### How effective is Shingrix vs placebo in adults 50 and older (ZOE-50)?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “Study 1 was a randomized, placebo-controlled, observer-blind clinical study conducted in 18 countries.”

Source: [SHINGRIX: Prescribing information, page 16, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=16)

> “Subjects were followed for the 
> development of HZ and postherpetic neuralgia (PHN) for a median of 3.1 years (range: 0 to 3.7 years).”

Source: [SHINGRIX: Prescribing information, page 16, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=16)

> “Compared with placebo, SHINGRIX significantly reduced the risk of developing HZ by 97.2% (95% CI: 93.7, 
> 99.0) in subjects aged 50 years and older (Table 4).”

Source: [SHINGRIX: Prescribing information, page 17, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=17)

<a id="shingrix-efficacy-by-age"></a>

### How effective is Shingrix by age group in adults 50 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “EFFICACY AGAINST SHINGLES BY AGE IN ADULTS ≥50 YEARS OLD<sup>1</sup>
> Age
>
> Efficacy
>
> Shingles cases (n) in SHINGRIX group (N)
>
> Shingles cases (n) in placebo group (N)
>
>
> 50-59 years old<sup>*</sup>
>
> 96.6%
>
> (95% CI: 89.6, 99.3)
>
>
>
> 3 (3492)
>
>
>
> 87 (3525)
>
>
>
> 60-69 years old<sup>*</sup>
>
> 97.4%
>
> (95% CI: 90.1, 99.7)
>
>
>
> 2 (2141)
>
>
>
> 75 (2166)
>
>
>
> 70-79 years old<sup>†</sup>
>
> 91.3%
>
> (95% CI: 86.0, 94.9)
>
>
>
> 19 (6468)
>
>
>
> 216 (6554)
>
>
>
> Age ≥80<sup>†</sup>
>
> 91.4%
>
> (95% CI: 80.2, 96.9)
>
>
>
> 6 (1782)
>
>
>
> 68 (1792)
>
> The studies were not designed to assess vaccine efficacy by pre-existing medical conditions.
>
> *
>
> Data from the ZOE-50 phase 3 trial.
>
> †
>
> Pooled data from ZOE-50 and ZOE-70 phase 3 trials.
>
> CI=confidence interval; n=number of subjects having ≥1 confirmed herpes zoster episode; N=number of subjects in each group.”

Source: [SHINGRIX: Vaccine Efficacy, captured 2026-11-13](https://shingrixhcp.com/efficacy-safety/efficacy-data/#:~:text=EFFICACY%20AGAINST%20SHINGLES%20BY%20AGE,of%20subjects%20in%20each%20group.)

> “Subjects were followed for the development of HZ and PHN for a median of 3.1 years (range: 0 to 3.7 years).<sup>1,3</sup>”

Source: [SHINGRIX: Vaccine Efficacy, captured 2026-11-13](https://shingrixhcp.com/efficacy-safety/efficacy-data/#:~:text=Subjects%20were%20followed%20for%20the,years%20%28range%3A%200%20to%203.7)

> “Subjects were followed for the development of HZ and PHN for a median of 4.0 years (range: 0 to 4.5 years).<sup>1,4</sup>”

Source: [SHINGRIX: Vaccine Efficacy, captured 2026-11-13](https://shingrixhcp.com/efficacy-safety/efficacy-data/#:~:text=in%20the%20mTVC.-,Subjects%20were%20followed%20for%20the%20development%20of%20HZ%20and%20PHN,years%20%28range%3A%200%20to%204.5)

Note: Results for ages 50 to 59 and 60 to 69 are from ZOE-50; results for ages 70 to 79 and 80 and older are from the pooled ZOE-50 and ZOE-70 analysis. Each comparison is with placebo in the modified Total Vaccinated Cohort. Median follow-up was 3.1 years in ZOE-50 and 4.0 years in the pooled analysis.

<a id="shingrix-efficacy-70-and-older"></a>

### How effective is Shingrix vs placebo in adults 70 and older?

Applies to: Adults aged 70 years and older (ZOE-70 and the pooled ZOE-50 and ZOE-70 analysis)

> “The efficacy of SHINGRIX to prevent HZ and PHN in subjects aged 70 years and older was evaluated by 
> combining the results from Studies 1 and 2 through a pre-specified pooled analysis in the mTVC. A total of 
> 8,250 and 8,346 subjects who received SHINGRIX and placebo, respectively, were included in the pooled 
> mTVC analysis.”

Source: [SHINGRIX: Prescribing information, page 19, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=19)

> “Compared with placebo, SHINGRIX significantly reduced the risk of developing HZ by 91.3% (95% CI: 86.9, 
> 94.5) in subjects aged 70 years and older (Table 6).”

Source: [SHINGRIX: Prescribing information, page 19, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=19)

> “Subjects were followed for the development of HZ and PHN for a median of 4.0 years (range: 0 to 4.5 years).<sup>1,4</sup>”

Source: [SHINGRIX: Vaccine Efficacy, captured 2026-11-13](https://shingrixhcp.com/efficacy-safety/efficacy-data/#:~:text=in%20the%20mTVC.-,Subjects%20were%20followed%20for%20the%20development%20of%20HZ%20and%20PHN,years%20%28range%3A%200%20to%204.5)

> “In a descriptive analysis, vaccine efficacy against HZ in subjects aged 70 years and older was 85.1% 
> (95% CI: 64.5, 94.8) in the fourth year after vaccination.”

Source: [SHINGRIX: Prescribing information, page 18, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=18)

Note: The pooled analysis combined ZOE-50 (Study 1) and ZOE-70 (Study 2); the fourth-year result is a descriptive analysis of ZOE-70. The pooled median follow-up of 4.0 years is from the Efficacy Data page of the Shingrix HCP site.

<a id="shingrix-phn-efficacy"></a>

### Does Shingrix reduce postherpetic neuralgia (PHN) vs placebo in adults 50 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “Among all subjects aged 50 years or older in the mTVC, no cases of PHN were reported in the vaccine group 
> compared with 18 cases reported in the placebo group.”

Source: [SHINGRIX: Prescribing information, page 17, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=17)

> “Among all subjects aged 70 years or older in the mTVC, 4 cases of PHN were reported in the vaccine group 
> compared with 28 cases reported in the placebo group. Vaccine efficacy against PHN was 85.5% 
> (95% CI: [58.5; 96.3]). The benefit of SHINGRIX in the prevention of PHN can be attributed to the effect of 
> the vaccine on the prevention of HZ.”

Source: [SHINGRIX: Prescribing information, page 18, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=18)

> “The benefit of SHINGRIX in the prevention of PHN can be attributed to the effect of the vaccine on the 
> prevention of HZ. The efficacy of SHINGRIX in the prevention of PHN in subjects with confirmed HZ could 
> not be demonstrated.”

Source: [SHINGRIX: Prescribing information, page 20, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=20)

Note: The first passage is from ZOE-50 (median follow-up 3.1 years) and the second from ZOE-70 (median follow-up 3.9 years). Shingrix is indicated for prevention of herpes zoster; the HCP site states that it is not indicated for the prevention of PHN or other herpes zoster-related complications.

<a id="shingrix-pain-medication"></a>

### Did Shingrix reduce shingles pain medication use vs placebo in adults 70 and older?

Applies to: Adults aged 70 years and older (ZOE-70 and the pooled ZOE-50 and ZOE-70 analysis)

> “Among subjects with confirmed HZ, the use of HZ-associated pain medications was reported for 10 of 23 
> subjects (43.5%) who received SHINGRIX and for 160 of 223 subjects (71.7%) who received placebo.”

Source: [SHINGRIX: Prescribing information, page 18, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=18)

Note: This result is from ZOE-70 (Study 2) and is limited to participants who developed confirmed herpes zoster.

<a id="shingrix-efficacy-stem-cell-transplant"></a>

### How effective is Shingrix vs placebo after autologous stem cell transplant?

Applies to: Immunocompromised adults aged 18 years and older who received an autologous hematopoietic stem cell transplant 50 to 70 days before the first dose (NCT01610414)

> “The efficacy of SHINGRIX was evaluated in 1 Phase 3 randomized, placebo-controlled, observer-blind clinical 
> study in immunocompromised adults aged ≥18 years who received an auHSCT 50 to 70 days prior to Dose 1 
> and who were expected to receive prophylactic antiviral therapy for ≤6 months post-transplant.”

Source: [SHINGRIX: Prescribing information, page 21, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=21)

> “SHINGRIX vs Placebo
>  	SHINGRIX	PLACEBO	 
> Age Group
> (years)	N/n	N/n	% Efficacy
> (95% Cl)
> Overall
> (≥18)<sup>§</sup>	870/49	851/135	68.2%
> (55.5, 77.6)
> 18 to 49	213/9	212/29	71.8%
> (38.7, 88.3)
> ≥50	657/40	639/106	67.3%
> (52.6, 77.9)
>
> * Median duration of follow-up period was 21 months (range: 0 to 49.4 months).
>
> <sup>†</sup> mTVC=modified total vaccinated cohort, defined as subjects who received 2 doses (0 and 1 to 2 months) of either SHINGRIX or placebo and did not develop a confirmed case of HZ within 1 month after the second dose. Follow-up was censored at the time of treatment for relapse.
>
> <sup>‡</sup> NCT01610414.
>
> <sup>§</sup> Primary study endpoint was based on confirmed HZ cases in subjects aged ≥18 years.
>
>
>
>
> auHSCT=autologous hematopoietic stem cell transplant; Cl=confidence interval; HZ=herpes zoster; N=number of subjects in each group; n=number of subjects having at least 1 confirmed HZ episode.”

Source: [SHINGRIX: Efficacy Data, captured 2026-11-13](https://shingrixhcp.com/home-ic/efficacy-safety/efficacy-data/#:~:text=SHINGRIX%20vs%20Placebo,least%201%20confirmed%20HZ%20episode.)

Note: The table is from the immunocompromised Efficacy Data page of the Shingrix HCP site; N/n gives the number of subjects in each group and the number with at least 1 confirmed herpes zoster episode.

<a id="shingrix-phn-stem-cell-transplant"></a>

### Does Shingrix reduce PHN vs placebo after autologous stem cell transplant?

Applies to: Immunocompromised adults aged 18 years and older who received an autologous hematopoietic stem cell transplant 50 to 70 days before the first dose (NCT01610414)

> “In the auHSCT study, subjects were followed for the development of HZ and PHN for a median of 21 months 
> (range: 0 to 49.4 months).”

Source: [SHINGRIX: Prescribing information, page 21, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=21)

> “Efficacy against Postherpetic Neuralgia: In a descriptive analysis, including all subjects aged ≥18 years in the 
> mTVC, 1 case of PHN was reported in the vaccine group compared with 9 cases reported in the placebo group. 
> Vaccine efficacy against PHN was 89.3% (95% CI: [22.5; 99.8]). The benefit of SHINGRIX in the prevention 
> of PHN can be attributed to the effect of the vaccine on the prevention of HZ.”

Source: [SHINGRIX: Prescribing information, page 22, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=22)

<a id="shingrix-pain-stem-cell-transplant"></a>

### Did Shingrix shorten shingles pain vs placebo after autologous stem cell transplant?

Applies to: Immunocompromised adults aged 18 years and older who received an autologous hematopoietic stem cell transplant 50 to 70 days before the first dose (NCT01610414)

> “In the auHSCT study, subjects were followed for the development of HZ and PHN for a median of 21 months 
> (range: 0 to 49.4 months).”

Source: [SHINGRIX: Prescribing information, page 21, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=21)

> “Herpes Zoster-Associated Pain: Subjects with suspected HZ rated their “worst” HZ-associated pain on a 
> 10-point scale. Among subjects with confirmed HZ, 37 out of 49 subjects (75.5%) receiving SHINGRIX and 
> 120 out of 135 subjects (88.9%) receiving placebo rated their “worst” HZ-associated pain as 3 or greater. In this”

Source: [SHINGRIX: Prescribing information, page 22, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=22)

> “subset of subjects, the median duration of “worst” HZ associated pain was 14 and 24 days, among SHINGRIX 
> and placebo recipients, respectively.”

Source: [SHINGRIX: Prescribing information, page 23, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=23)

Note: The comparison is limited to auHSCT study participants who developed confirmed herpes zoster.

<a id="shingrix-efficacy-hematologic-malignancies"></a>

### How effective was Shingrix vs placebo in hematologic malignancies (post hoc analysis)?

Applies to: Immunocompromised adults aged 18 years and older with hematologic malignancies vaccinated during or within 6 months of immunosuppressive chemotherapy (NCT01767467)

> “The efficacy of 
> SHINGRIX was calculated post hoc in another randomized, placebo-controlled, observer-blind study in subjects 
> with hematologic malignancies who received Dose 1 of SHINGRIX or placebo during or within 6 months of 
> completing immunosuppressive chemotherapy.”

Source: [SHINGRIX: Prescribing information, page 21, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=21)

> “Subjects were followed for the development of HZ for a median of 
> 11.1 months (range: 0 to 15.6 months). PHN was not assessed as a study endpoint.”

Source: [SHINGRIX: Prescribing information, page 22, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=22)

> “In the hematologic malignancy study, the population for the post hoc efficacy analysis included 515 subjects 
> who received 2 doses of either SHINGRIX or placebo and did not develop a confirmed case of HZ within 
> 1 month after the second dose. Confirmed HZ cases were determined by either PCR (81.3%) or by a Clinical 
> Evaluation Committee (18.7%). The post hoc analysis showed SHINGRIX was 87.2% (95% CI [44.2; 98.6]) 
> effective against development of HZ. The incidence rate of HZ per 1,000 person-years was 8.5 versus 66.2 in 
> the SHINGRIX and placebo groups, respectively.”

Source: [SHINGRIX: Prescribing information, page 22, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=22)

Note: This efficacy result is from a post hoc analysis, and postherpetic neuralgia was not a study endpoint.

## Long-term results

<a id="shingrix-year-4-efficacy"></a>

### How effective is Shingrix vs placebo in year 4 in adults 50 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “In a descriptive analysis, vaccine efficacy against HZ in subjects aged 50 years and older was 93.1% 
> (95% CI: 81.3, 98.2) in the fourth year postvaccination.”

Source: [SHINGRIX: Prescribing information, page 17, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=17)

> “In a descriptive analysis, vaccine efficacy against HZ in subjects aged 70 years and older was 85.1% 
> (95% CI: 64.5, 94.8) in the fourth year after vaccination.”

Source: [SHINGRIX: Prescribing information, page 18, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=18)

Note: Both results are descriptive analyses compared with placebo: the first from ZOE-50 (adults 50 and older) and the second from ZOE-70 (adults 70 and older).

<a id="shingrix-long-term-follow-up"></a>

### What did Shingrix long-term follow-up show through about 11 years in adults 50+?

Applies to: Adults aged 50 years and older vaccinated in ZOE-50 or ZOE-70 and followed in the long-term follow-up study (ZOSTER-049)

> “Historical controls were used to estimate the long-term efficacy of SHINGRIX.”

Source: [SHINGRIX: Vaccine Efficacy, captured 2026-11-13](https://shingrixhcp.com/efficacy-safety/efficacy-data/#:~:text=Historical%20controls%20were%20used%20to%20estimate%20the%20long%2Dterm%20efficacy%20of%20SHINGRIX.)

> “Open-label, phase 3b, multicenter extension study of the ZOE-50/-70 clinical trials
>
>
> Among the 13,881 patients from the mTVC who received SHINGRIX in the ZOE-50/-70 trials, 7273 participants were included in the mTVC of the extension trial<sup>*</sup>
> Participants who received placebo in the ZOE-50/-70 studies were offered vaccination with SHINGRIX at study completion. No unvaccinated placebo group was available in the LTFU study; a historical control constructed with ZOE-50/-70 placebo data was used for the vaccine efficacy calculation for LTFU
> In the LTFU study, participants were followed for up to 6 years (starting at a median of 5.6 years post-vaccination in ZOE-50/-70 and ending at a median of 11.4 years post-vaccination)
> HZ cases during the gap period between ZOE-50/-70 and the LTFU study were not considered in the VE analysis”

Source: [SHINGRIX: Vaccine Efficacy, captured 2026-11-13](https://shingrixhcp.com/efficacy-safety/efficacy-data/#:~:text=Open%2Dlabel%2C%20phase%203b%2C%20multicenter%20extension,considered%20in%20the%20VE%20analysis)

> “Consider open-label extension study limitations when interpreting results. The open-label extension study was not blinded, all statistical analyses were descriptive, historical controls were utilized, and the results may be subject to analyst bias
> No direct matching process was utilized for historical controls. Use of historical controls could overestimate efficacy
> The methodology used assumes incidence rates in the historical control group remain stable over time and does not account for factors external to the study that may affect incidence of HZ (eg, trends in HZ over time and the COVID-19 pandemic)”

Source: [SHINGRIX: Vaccine Efficacy, captured 2026-11-13](https://shingrixhcp.com/efficacy-safety/efficacy-data/#:~:text=Consider%20open%2Dlabel%20extension%20study%20limitations,time%20and%20the%20COVID%2D19%20pandemic%29)

> “Primary objective:
> Vaccine efficacy against HZ during the LTFU in adults ≥50 YOA* 
>
> 79.8
>
> %
>
> (95% CI: 73.7, 84.6)
>
> n/N: 69/7258 SHINGRIX vs 341/7258 historical controls<sup>†</sup>
>
> Incidence rates<sup>‡</sup>: 1.8 SHINGRIX vs 8.7 historical controls<sup>†</sup>”

Source: [SHINGRIX: Vaccine Efficacy, captured 2026-11-13](https://shingrixhcp.com/efficacy-safety/efficacy-data/#:~:text=Primary%20objective%3A,1.8%20SHINGRIX%20vs%208.7%20historical)

> “Overall vaccine efficacy against HZ in adults ≥50 YOA<sup>*,†</sup> from 1 month post-dose 2 in ZOE-50/-70 to the end of the LTFU
>
> 87.7
>
> %
>
> (95% CI: 84.9, 90.1)
>
> n/N: 101/13,881 SHINGRIX<sup>‡</sup> vs 818/14,035 placebo/historical controls<sup>§</sup>”

Source: [SHINGRIX: Vaccine Efficacy, captured 2026-11-13](https://shingrixhcp.com/efficacy-safety/efficacy-data/#:~:text=Overall%20vaccine%20efficacy%20against%20HZ,vs%20818%2F14%2C035%20placebo%2Fhistorical)

> “Historical control group: based on data from the placebo groups of the parent studies (ZOE-50/-70) with the number of participants (N) and follow-up time assumed to be the same as the vaccinated group.”

Source: [SHINGRIX: Vaccine Efficacy, captured 2026-11-13](https://shingrixhcp.com/efficacy-safety/efficacy-data/#:~:text=Historical%20control%20group%3A%20based%20on,same%20as%20the%20vaccinated%20group.)

Note: The long-term follow-up results are descriptive and compare vaccinated participants with a historical control constructed from the ZOE-50 and ZOE-70 placebo groups; the page lists the limitations of this method.

<a id="shingrix-long-term-by-age"></a>

### How effective is Shingrix long term by age at vaccination?

Applies to: Adults aged 50 years and older vaccinated in ZOE-50 or ZOE-70 and followed in the long-term follow-up study (ZOSTER-049)

> “Select secondary objective: Vaccine efficacy against HZ by age strata during the LTFU study
>
> Age 50-59 years*
>
> 86.7
>
> %
>
> (95% CI: 75.6, 93.4)
>
> n/N: 12/2043 SHINGRIX vs 90/2043 historical controls<sup>†</sup>
>
> Incidence rates<sup>‡</sup>: 1.0 SHINGRIX vs 7.7 historical controls<sup>†</sup>
>
> Age 60-69 years*
>
> 87.1
>
> %
>
> (95% CI: 74.2, 94.4)
>
> n/N: 9/1242 SHINGRIX vs 70/1242 historical controls<sup>†</sup>
>
> Incidence rates<sup>‡</sup>: 1.3 SHINGRIX vs 10.1 historical controls<sup>†</sup>
>
> Age 70-79 years*
>
> 71.9
>
> %
>
> (95% CI: 60.1, 80.6)
>
> n/N: 41/3349 SHINGRIX vs 146/3349 historical controls<sup>†</sup>
>
> Incidence rates<sup>‡</sup>: 2.3 SHINGRIX vs 8.3 historical controls<sup>†</sup>
>
> Age ≥80 years*
>
> 75.9
>
> %
>
> (95% CI: 43.7, 91.1)
>
> n/N: 7/624 SHINGRIX vs 29/624 historical controls<sup>†</sup>
>
> Incidence rates<sup>‡</sup>: 2.5 SHINGRIX vs 10.5 historical controls<sup>†</sup>”

Source: [SHINGRIX: Vaccine Efficacy, captured 2026-11-13](https://shingrixhcp.com/efficacy-safety/efficacy-data/#:~:text=Select%20secondary%20objective%3A%20Vaccine%20efficacy,2.5%20SHINGRIX%20vs%2010.5%20historical)

> “Among subjects 50 through 59 years, 60 through 69 years, 70 through 79 years, 
> and 80 years or older at the time of vaccination, the incidence rates of HZ over the duration of the LTFU study 
> were 1.0, 1.3, 2.3, and 2.5 per 1,000 person-years, respectively. In the LTFU study, the incidence rates by age 
> group were higher than the incidence rates of HZ reported by age group in the SHINGRIX groups in Study 1 
> and in the pooled analysis of Studies 1 and 2 (which were 0.3, 0.3, 0.8, and 1.0 per 1,000 person-years, 
> respectively [see Tables 4 and 6]). The incidence rates were lower than those reported by age group in the 
> placebo groups in Study 1 and in the pooled analysis of Studies 1 and 2 (which were 7.8, 10.8, 8.9 and 11.1 per 
> 1,000 person-years, respectively [see Tables 4 and 6]). In Studies 1 and 2, the median follow-up time after 
> vaccination was 3.1 and 3.9 years, respectively.”

Source: [SHINGRIX: Prescribing information, page 21, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=21)

Note: These are descriptive long-term follow-up results compared with a historical control from the ZOE-50 and ZOE-70 placebo groups, starting at a median of 5.6 years and ending at a median of 11.4 years after vaccination.

## Related pages
- [Medical information: Shingrix (Zoster Vaccine Recombinant, Adjuvanted): Herpes zoster prevention](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention)
- [Indication](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/indication)
- [Safety](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/safety)
- [Specific populations](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/guidelines)
